Key facts
- Kairos Pharma signed a term sheet for an acquisition.
- The acquisition target is a lung cancer asset.
- Financial details were not disclosed.
Kairos Pharma has announced the signing of a term sheet, indicating a preliminary agreement to acquire a lung cancer asset. The company has not yet disclosed the financial terms associated with this potential transaction. This move suggests Kairos Pharma's strategic interest in expanding its portfolio within the oncology sector, specifically targeting lung cancer treatments.